Read by QxMD icon Read


Abigail E Besemer, You Ming Yang, Joseph J Grudzinski, Lance T Hall, Bryan P Bednarz
This work describes the development and validation of a patient-specific Monte Carlo internal dosimetry platform called RAPID (Radiopharmaceutical Assessment Platform for Internal Dosimetry). RAPID utilizes serial PET/CT or SPECT/CT images to calculate voxelized three-dimensional (3D) internal dose distributions with the Monte Carlo code Geant4. RAPID's dosimetry calculations were benchmarked against previously published S-values and specific absorbed fractions (SAFs) calculated for monoenergetic photon and electron sources within the Zubal phantom and for S-values calculated for a variety of radionuclides within spherical tumor phantoms with sizes ranging from 1 to 1000 g...
April 25, 2018: Cancer Biotherapy & Radiopharmaceuticals
Giorgio Treglia, Andor W J M Glaudemans, Francesco Bertagna, Bouke P C Hazenberg, Paola A Erba, Raffaele Giubbini, Luca Ceriani, John O Prior, Luca Giovanella, Riemer H J A Slart
PURPOSE: Cardiac transthyretin-related amyloidosis (ATTR) is a progressive and fatal cardiomyopathy. The diagnosis of this disease is frequently delayed or missed due to the limited specificity of echocardiography. An increasing amount of data in the literature demonstrate the ability of bone scintigraphy with bone-seeking radiopharmaceuticals to detect myocardial amyloid deposits, in particular in patients with ATTR. Therefore we performed a systematic review and bivariate meta-analysis of the diagnostic accuracy of bone scintigraphy in patients with suspected cardiac ATTR...
April 23, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Heather Jacene, Leonard Gomella, Evan Y Yu, Eric M Rohren
Radium-223 dichloride is an α-emitting radiopharmaceutical that localizes to bone matrix and is approved for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. The cumulative impact of Ra-223 and other therapeutic agents for metastatic CRPC on myelosuppression in bone marrow is unknown. The phase 3 randomized, double-blind, placebo-controlled ALSYMPCA trial of Ra-223 in patients with CRPC and symptomatic bone metastases demonstrated a significant improvement in overall survival...
March 23, 2018: Clinical Genitourinary Cancer
B Beuthien-Baumann
Positron emission tomography (PET) is a procedure in nuclear medicine, which is applied predominantly in oncological diagnostics. In the form of modern hybrid machines, such as PET computed tomography (PET/CT) and PET magnetic resonance imaging (PET/MRI) it has found wide acceptance and availability. The PET procedure is more than just another imaging technique, but a functional method with the capability for quantification in addition to the distribution pattern of the radiopharmaceutical, the results of which are used for therapeutic decisions...
April 19, 2018: Der Radiologe
Suisheng Yang, Weiyu Bao, Xiaorong Bai, Chen Gao, Binming Zhang, Zhuanji Jiang
Aim: The aim of this study was to assess the sentinel lymph node (SLN) detection rate and accuracy of 99m Tc-labeled sodium phytate and stannous chloride (99m Tc-PHY) injection versus 99m Tc-labeled sulfur colloid (99m Tc-SC) injection in sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer. Methods: A total of 146 consecutive female patients with early stage breast cancer were recruited in this open-labeled, randomized, controlled study...
2018: OncoTargets and Therapy
Malgorzata Wrzesien, Leszek Krolicki, Lukasz Albiniak, Jerzy Olszewski
INTRODUCTION: The specificity of personnel exposure, which distinguishes nuclear medicine, is associated with the form of the radiation source used, and this often requires performing manual procedures while using radioactive isotopes. The variety of radionuclides and medical procedures, and the yearly increase in the number of patients, as well as the change of the individual dose limit for the lens of the eye from a value of 150 mSv per year to a level of 20 mSv, means that issues of eye lens routine dosimetry become interesting from the radiation protection point of view...
April 18, 2018: Journal of Radiological Protection: Official Journal of the Society for Radiological Protection
Mohammed Al-Qahtani, Yousif Al Malki, Hadeel Mutwali, Edward Helal-Neto, Ralph Santos-Oliveira
BACKGROUND AND OBJECTIVE: The future of medicine relies on the capability to forecast the future and in the development of new drugs. The same rationale is applied to radiopharmacy. In this direction the development of nano-radiopharmaceuticals represents the most effective glance of the future. METHODS: In this manuscript we developed an efficient, rapid and direct methodology to label ultra-small polymeric nanoparticle (10 to 12 nm) and regular polymeric nanoparticles (200 to 210 nm), both obtained by double emulsion technique, with Ga-68 in order to promote the development of PET-nanoradiopharmaceuticals...
April 17, 2018: Current Radiopharmaceuticals
Ida Sonni, Lucia Baratto, Sonya Park, Negin Hatami, Shyam Srinivas, Guido Davidzon, Sanjiv Sam Gambhir, Andrei Iagaru
BACKGROUND: A newly introduced PET/CT scanner (Discovery Meaningful Insights-DMI, GE Healthcare) includes the silicon photomultiplier (SiPM) with time-of-flight (TOF) technology first used in the GE SIGNA PET/MRI. In this study, we investigated the impact of various acquisition times on image quality using this SiPM-based PET/CT. METHODS: We reviewed data from 58 participants with cancer who were scanned using the DMI PET/CT scanner. The administered dosages ranged 295...
April 18, 2018: EJNMMI Physics
Tamer Nasr, Samir Bondock, Hassan M Rashed, Walid Fayad, Mahmoud Youns, Tamer M Sakr
The current work presents the synthesis and biological evaluation of new series of coumarin hydrazide-hydrazone derivatives that showed in vitro broad spectrum antitumor activities against resistant pancreatic carcinoma (Panc-1), hepatocellular carcinoma (HepG2) and leukemia (CCRF) cell lines using doxorubicin as reference standard. Bromocoumarin hydrazide-hydrazone derivative (BCHHD) 11b showed excellent anticancer activity against all tested cancer cell lines. Enzyme assays showed that BCHHD 11b induced apoptosis due to activation of caspases 3/7...
April 9, 2018: European Journal of Medicinal Chemistry
Fransiska Kurniawan, Rahmana E Kartasasmita, Naoki Yoshioka, Abdul Mutalib, Daryono H Tjahjono
Melanoma is the most aggressive type of skin cancer. Metastatic melanoma is extremely difficult to treat with current therapy methods such as surgery. On the other hand, it is a good opportunity to develop a radiopharmaceutical using a radionuclide such as technetium (Tc) for diagnostic and rhenium (Re) for therapeutic purposes. T3,4BCPP has been be used as a radioimaging agent for melanoma cancers experimentally. The aim of the present research was to design new imidazolylporphyrin derivatives with better selectivity and higher affinity than those of T3,4BCPP by molecular modeling...
April 16, 2018: Current Computer-aided Drug Design
Piotr F J Lipiński, Piotr Garnuszek, Michał Maurin, Raphael Stoll, Nils Metzler-Nolte, Artur Wodyński, Jan Cz Dobrowolski, Marta K Dudek, Monika Orzełowska, Renata Mikołajczak
BACKGROUND: The cholecystokinin receptor subtype 2 (CCK-2R) is an important target for diagnostic imaging and targeted radionuclide therapy (TRNT) due to its overexpression in certain cancers (e.g., medullary thyroid carcinoma (MTC)), thus matching with a theranostic principle. Several peptide conjugates suitable for the TRNT of MTC have been synthesized, including a very promising minigastrin analogue DOTA-(DGlu)6 -Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (CP04). In this contribution, we wanted to see whether CP04 binding affinity for CCK-2R is sensitive to the type of the complexed radiometal, as well as to get insights into the structure of CP04-CCK2R complex by molecular modeling...
April 16, 2018: EJNMMI Research
Emily Curnock, William Levason, Mark E Light, Sajinder K Luthra, Graeme McRobbie, Francesco M Monzittu, Gillian Reid, R Nathan Williams
Fluorination of [ScCl3(Me3-tacn)] (Me3-tacn = 1,4,7-trimethyl-1,4,7-triazacyclononane) and [ScCl3(BnMe2-tacn)] (BnMe2-tacn = 1,4-dimethyl-7-benzyl-1,4,7-triazacyclononane) by Cl/F exchange with 3 mol. equiv. of anhydrous [NMe4]F in CH3CN solution yields the corresponding [ScF3(R3-tacn)] (R3 = Me3 or BnMe2). These are the first examples of scandium fluoride complexes containing neutral co-ligands. The fluorination occurs stepwise, and using a deficit of [NMe4]F produced [ScF2Cl(Me3-tacn)]. Attempts to fluorinate [YCl3(Me3-tacn)], [YI3(Me3-tacn)], [LaCl3(Me3-tacn)(OH2)] or [MCl3(terpy)] (M = Sc, Y or La; terpy = 2,2':6'2''-terpyridyl) using a similar method were unsuccessful, due to the Cl/F exchange being accompanied by loss of the neutral ligand from the metal centre...
April 17, 2018: Dalton Transactions: An International Journal of Inorganic Chemistry
M A Motaleb, Adli A Selim, M El-Tawoosy, M H Sanad, M A El-Hashash
PURPOSE: dioxime derivative is reported to exhibit high affinity towards tumor cells. The objective of the present study is to synthesis a new dioxime derivative to be labeled with technetium-99m for using as solid tumor marker. MATERIALS AND METHODS: ((2E,2'E,3E,3'E)-3,3'-(cyclohexane-1,2-diylbis (azanylylidene)) bis-(butan-2-one)dioxime was synthesized by condensation of Butan-2,3-dione monooxime and diaminocyclohexane and labeled with 99m Tc, The in-vivo distribution of the agent were studied by carrying out biodistribution in tumor bearing Albino mice...
April 16, 2018: International Journal of Radiation Biology
Cristina Müeller, Katharina A Domnanich, Christoph A Umbricht, Nicholas P van der Meulen
Currently, different radiometals are in use for imaging and therapy in nuclear medicine: 68 Ga and 111 In are examples of nuclides for positron emission tomography (PET) and single photon emission computed tomography (SPECT), respectively, while 177 Lu and 225 Ac are used for β- - and α-radionuclide therapy. The application of diagnostic and therapeutic radionuclides of the same element (radioisotopes) would utilize chemically-identical radiopharmaceuticals for imaging and subsequent treatment, thereby enabling the radiotheranostic concept...
April 16, 2018: British Journal of Radiology
A Kh Robertson, C F Ramogida, P Schaffer, V Radchenko
The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide. Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields...
April 16, 2018: Current Radiopharmaceuticals
(no author information available yet)
Corrigendum to ICRP Publication 128: Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. [Ann. ICRP 44(2S), 2015]. DOI: 10.1177/0146645314558019 . The following error has been identified in Table C.109, p. 280: The value of the absorbed dose per unit activity administered to the urinary bladder wall for the 1-year-old child after oral administration of 131 I-iodide should be 1.3E+00 mGy MBq-1 , not 1.3E-01 as was originally stated...
January 1, 2018: Annals of the ICRP
Sung-Hyun Moon, Mee Kyung Hong, Young Ju Kim, Yun-Sang Lee, Dong Soo Lee, June-Key Chung, Jae Min Jeong
Glu-Urea-Lys (GUL) derivatives have been reported as prostate-specific membrane antigen (PSMA) agent. We developed derivatives of GUL conjugated with NOTA or DOTA via a thiourea linker and tested their feasibility as PSMA imaging agents after labeling with 68 Ga. NOTA-GUL and DOTA-GUL were synthesized and labeled with 68 Ga using generator-eluted 68 GaCl3 in 0.1 M HCl in the presence of 1 M NaOAc at pH 5.5. The stabilities of 68 Ga-labeled compounds in human serum were tested at 37.5 °C. A competitive binding assay was performed using the PSMA-positive prostate cancer cell line 22Rv1 and [125 I]MIP-1072 (PSMA-specific binding agent) as a tracer...
April 5, 2018: Bioorganic & Medicinal Chemistry
Nafise Salek, Sara Vosoghi, Simindokht Shirvani Arani, Ali Bahrami Samani, Mohsen Mehrabi, Mohammad Ghannadi Maraghe
BACKGROUND AND OBJECTIVE: Skeletal uptake of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is used to deliver high doses of this radiopharmaceutical to the bone marrow. METHODS: In this research, carrier-free (c.f.) 90Y was obtained from an electrochemical 90Sr/90Y generator. The c.f. 90Y was mixed with 300 µL of DOTMP (20 mg/mL) and incubated under stirring conditions at room temperature for 45 min. RESULTS: The [90Y]Y-DOTMP that was obtained under optimized reaction conditions had the high radiochemical purities (>98%)...
April 12, 2018: Current Radiopharmaceuticals
J D Harrison
The practical implementation of the International Commission on Radiological Protection's (ICRP) system of radiological protection requires the availability of appropriate methodology and data. Over many years, ICRP Committee 2 has provided sets of dose coefficients to allow users to evaluate equivalent and effective doses for radiation exposures of workers and members of the public. The methodology being applied in the calculation of doses is state-of-the-art in terms of the biokinetic models used to describe the behaviour of inhaled and ingested radionuclides, and the dosimetric models used to model radiation transport for external and internal exposures...
January 1, 2018: Annals of the ICRP
Daniel W Sonnenburg, Alicia K Morgans
PURPOSE OF REVIEW: In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy. RECENT FINDINGS: Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy...
April 11, 2018: Current Oncology Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"